Background: To assess bioactive transforming growth factor-β2 (TGFβ2) and secreted frizzled-related protein-1 (SFRP1) levels in aqueous humor (AH) of different types of glaucoma.
Background
Glaucoma is a leading cause of irreversible blindness in the world. According to the anatomical shape of the anterior chamber angle, glaucoma can be divided into open-angle glaucoma (OAG) and angle-closure glaucoma (ACG). It is projected that primary open angle glaucoma (POAG) will affect 53 million people while primary angle-closure glaucoma (PACG) will affects 23 million worldwide in 2020 [1] . In PACG patients, the outflow pathway of aqueous humor (AH) is obstructed anatomically by apposition of the iris [2] , whereas in POAG, ocular hypertension is a result of increased AH outflow resistance in the trabecular meshwork (TM), which is likely associated with increased local deposition of extracellular matrix and stiffening of the tissue [3] [4] [5] .
The exact mechanism of pathogenesis in glaucoma is not known. However, elevated levels of several cytokines, such as transforming growth factor β2 (TGFβ2) and secreted frizzled-related protein 1 (SFRP1), have been detected in the AH and/or TM of POAG patients. For example, TGFβ2 levels are higher in AH samples of POAG patients [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . TGFβ2 is produced by tissues in the anterior segment of eye and affects TM cell functions, such as extracellular matrix metabolism, contractility, phagocytosis and proliferation [16] [17] [18] [19] [20] [21] [22] . The cellular functions of TGFβ2 likely translate to elevation of intraocular pressure (IOP). Perfusion of ex vivo human anterior segments with TGFβ2 increases IOP, corresponding to an increased accumulation of extracellular matrix in the TM region [17, 23] . Most importantly, intraocular injection of an adenoviral vector encoding a biologically active form of TGFβ2 increases IOP in both the rat and mouse [24] [25] [26] .
SFRP1 is an antagonist of the Wnt signaling pathway, which has been localized in many cells and tissues [27] , including the human TM [28] . By preventing Wnt from activating its receptor, SFRP1 blocks the Wnt effects on normal cellular functions and decreases the intracellular level of catenin. In cultured TM cells derived from POAG patients, SFRP1 expression was significantly higher than non-glaucoma controls, concomitant with a decrease in catenin level [29] . Treatment of ex vivo perfused human anterior segments with recombinant SFRP1 reduced AH outflow facility [29] . Intravitreal injection of adenoviral vector encoding SFRP1 increases ocular expression of the protein and raises IOP in the mouse [28, 29] , clearly indicating a potential contributory role in glaucoma. However, SFRP1 levels in AH of glaucoma patients have not been reported.
Although these two cytokines are elevated in TM tissues of POAG patients, it is not clear whether the two proteins are simultaneously increased in the same patients and if their levels in AH samples of ACG patients are changed. It is also not known if the concentrations of these two cytokines correlate with IOP. To attempt to address these questions, we evaluated the two cytokines levels in AH of POAG and ACG patients to investigate the involvement of these cytokines in glaucomas.
Materials and methods

Patient and sample collection
This study protocol was approved by the Research Ethics Committee of the Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, and adhered to the tenets of the Helsinki Declaration. All patients provided written informed consent.
The AH samples were collected from 126 eyes of 105 patients, who were divided into the following groups: cataract patients who did not have any other known ocular disorders (n = 26 eyes of 24 patients; serving as controls), POAG (n = 25 eyes of 21 patients), chronic ACG (CACG) (n = 21 eyes of 19 patients), primary angle-closure suspects (PACS) (n = 9 eyes of 9 patients), and acute ACG (AACG) (n = 45 eyes of 32 patients).
All patients underwent careful and detailed ophthalmologic evaluations, including anterior chamber angle, visual field, optic disc morphology and IOP. All patients had no history of trabeculectomy or laser iridotomy surgeries. POAG was defined as the presence of glaucomatous optic nerve damage, visual field loss and normal angle on gonioscopy. CACG was defined as the existence of a gonioscopically occludable angle accompanied by glaucomatous optic neuropathy and compatible visual field defects. Eyes with an occludable drainage angle, but normal optic disc, visual field, IOP, and no peripheral anterior synechiae were diagnosed as PACS. The following criteria were used to define cases of AACG: (1) presence of at least two of the following symptoms: ocular or periocular pain, nausea or vomiting, headache, an antecedent history of intermittent blurring of vision with haloes; (2) presenting of an occluded angle on gonioscopy and IOP > 21 mmHg; (3) the presence of at least three of the following signs: conjunctival injection, corneal epithelial edema, mid-dilated unreactive pupil, and shallow anterior chamber.
Cataract and PACS patients did not receive any ophthalmic medication within one month prior to AH collection. All patients of the POAG and CACG groups were on anti-glaucoma eye drops that included betablockers, carbonic anhydrase inhibitors, and alpha-adrenergic agonists. In the AACG group, most patients received the same medications, except for eight patients, who experienced their first AACG attack with high IOP (> 40 mmHg). AH samples of these eight patients were collected while they were treated by anterior chamber puncture. AH samples of other patients in our study were collected by at the time of cataract or glaucoma surgery after medical treatment. The patients underwent IOP measurement by a Goldmann applanation tonometer within half an hour before AH sample collection. Within each of the POAG, CACG, and AACG groups, for additional analysis, we further divided the patients into two sub-groups, those whose IOP values were managed by therapeutic means to ≤21 mmHg, and those whose IOP were > 21 mmHg. Characterizations of the patients in each group are listed in Table 1 .
Approximately 150 μL of AH was obtained at the time of anterior chamber puncture treatment and cataract or glaucoma surgery with a 27-gauge needle attached to a microsyringe. During AH collection, the needle was carefully positioned to avoid touching the corneal endothelium, iris, or lens. Free of blood contamination was visually confirmed. The samples were placed into Eppendorf tubes and stored at − 80°C until analyzed.
ELISA assays for TGFβ2 and SFRP1
Prior to assay, the thawed AH samples were centrifuged at 4°C to remove potential debris. The concentration of the bioactive form of TGFβ2 in AH was measured by enzyme-linked immunosorbent assay (DB250, R&D Systems, Minneapolis, MN, USA). After adding 100 μL of ELISA assay diluent, 100 μL bioactive TGFβ2 standard or diluted AH samples were added to each well and incubated for 2 h at room temperature. Each well was washed 3 times with 400 μL wash buffer and 200 μL anti-TGFβ2 polyclonal antibody conjugated to horseradish peroxidase was added. The mixture was then incubated and washed. An aliquot of 200 μL substrate solution was added, and plates, protected from light, were incubated for 20 min at room temperature. Stop solution (50 μL) was then added to each well, and the absorbance at 450 nm was measured with a microplate reader (Pierce, Rockford, IL, USA).
The level of SFRP1 was also assayed by ELISA (ELH-SFRP1, RayBiotech, Norcross, GA, USA). Briefly, either 100 μL SFRP1 standard or diluted AH sample was added to each well. After 2.5 h incubation at room temperature with gentle shaking, the wells were washed four times with 300 μL buffer. Each well was coated with 100 μL of biotinylated anti-SFRP1 antibody and incubated for 1 h at room temperature. After being washed again, 100 μL stop solution was added to each well and the absorbance was measured similar to the TGFβ2 ELISA.
Statistical analysis
Results are represented as mean ± SEM. Comparison among three or more groups was performed using oneway analysis of variance (ANOVA), followed by Dunnett's test. Comparison between two groups was conducted by t-test. The correlation between two parameters was assessed by linear regression analysis. Statistical significance was set at P < 0.05 and all analyses were performed using SPSS 19.0.
Results
Levels of bioactive TGFβ2 and SFRP1 in AH
Our results show that the concentration of bioactive TGFβ2 in AH in control (cataract) eyes was 345.2 ± 24.8 pg/ml (mean ± SEM, n = 26) (Fig. 1a) . This value corroborates very well with the majority of previously published reports (Additional file 1: Figure S1 , [7] [8] [9] [10] [11] [12] 14] . AH samples from POAG eyes had a bioactive TGFβ2 level of 465.9 ± 33.9 pg/ml (n = 25), which was significantly higher than that of control eyes (Fig. 1a) (P = 0.01). This finding again confirms prior observations that bioactive TGFβ2 level in AH samples of POAG patients are significantly higher than cataract controls [7] [8] [9] [10] [11] [12] 14] . In comparison, there was no significant difference in concentrations of bioactive TGFβ2 between control eyes and CACG eyes (344.6 ± 37.4 pg/ml, n = 21) (P = 0.99), PACS eyes (336.0 ± 54.3 pg/ml, n = 9) (P = (Fig. 1a ). There were measureable levels of SFRP1 in AH samples. In cataract samples, a level of 1.88 ± 0.10 ng/ml was observed (Fig. 1b) . Interestingly, SFRP1 levels in AH samples from patients with POAG (1.98 ± 0.12 ng/ml) (P = 0.54), CACG (1.71 ± 0.13 ng/ml) (P = 0.34), PACS (1.84 ± 0.18 ng/ml) (P = 0.85) and AACG (1.97 ± 0.10 ng/ ml) (P = 0.53) were not significantly different from that of controls (Fig. 1b) .
Correlation between IOP and AH levels of TGFβ2 and SFRP1
To evaluate whether there was a correlation between IOP and the cytokines, we compared IOP within each disease group with the respective concentration of active TGFβ2 and SFRP1. The results indicate that within the control, POAG, PACS, and CACG groups, the IOP of the evaluated eyes at the time AH was collected did not correlate with TGFβ2 levels (P > 0.05), although a positive slope was observed in the POAG and CACG groups (Fig. 2a-d) . Most importantly, a significant (P = 0.0024) correlation between the concentration of active TGFβ2 and IOP was detected in the AACG group (Fig. 2e) . This finding led us to further divide the samples of this group into those whose IOP was successfully controlled to ≤21 mmHg (normal IOP), and those whose IOP was above 21 mmHg (high IOP). In doing so, the bioactive TGFβ2 levels were significantly (P = 0.006) different between these two groups: the level in "AACG with normal IOP" group was 242.8 ± 29.5 pg/ml (n = 15), and that in "AACG with high IOP" group was 394.6 ± 33.6 pg/ml (n = 30) (Fig. 3c) . Using the same IOP criterion to divide samples in the POAG or CAGG groups into normal and high IOP sub-groups did not show significantly different TGFβ2 levels between the sub-groups (Fig. 3a, b) .
When we evaluated the relationship between IOP and AH levels of SFRP1, we unexpectedly found a statistically significant, negative correlation between the SFRP1 level and IOP in the POAG group (P = 0.011) (Fig. 4b) , while no significant (P > 0.05) correlation was observed between IOP and AH concentration of SFRP1 in cataract, PACS, AACG or CACG group (Fig. 4a, c, d, e) . Interestingly, this correlation in the AACG group was positive and closed to being statistically significant (P = 0.0859) (Fig. 4e) . Sub-dividing patients in POAG, AACG and CACG groups into those with normal IOP (≤ 21 mmHg) and those with high IOP (> 21 mmHg) confirmed these observations. The SFRP1 level in POAG with normal IOP (2.18 ± 0.11 ng/ml, n = 15) was significantly (P = 0.032) higher than that of the high IOP subgroup (1.69 ± 0.21 ng/ml, n = 10) (Fig. 3d) . In the subgroups of AACG patients, the relationship was reversed, such that the SFRP1 level in AACG with high IOP (2.19 ± 0.10 ng/ml, n = 30) was significantly (P = 0.001) lower than that of AACG with normal IOP (1.53 ± 0.18 ng/ml, n = 15) (Fig. 3f ) . In CACG patients, SFRP1 levels between normal and high IOP subgroups are not significantly different from each other (Fig. 3e) .
Correlation between medication, age and AH levels of TGFβ2 and SFRP1
To evaluate if changes of TGFβ2 and SFRP1 are associated with each other, we analyzed the correlation of levels between these two cytokines. There was no statistically significant correlation between the concentrations of active TGFβ2 and SFRP1 in the AH within each of the study groups (Fig. 5) .
In the AACG group, 37 AH samples were obtained from patients treated with anti-glaucoma medication, and 8 samples were from patients who were not treated with medication. In order to analyze whether anti-glaucoma medications affected the experimental results, we divided AACG patients with high IOP into "drugs" group and "no drug" group, and found that there was not significantly difference in concentrations of bioactive TGFβ2 and SFRP1 between these two groups (Additional file 2: Figure S2 ). These findings suggest that anti-glaucoma medical treatment had no effect on the levels of TGFβ2 and SFRP1 within each group. The same analysis was not performed in the other groups, since all patients in the cataract and PACS groups did not receive any medication, and all patients in the POAG and CACG groups received antiglaucoma eye drops. We also analyzed the relationship between age and concentration of active TGFβ2 and SFRP1 levels in the AH. We did not detect any statistically significant correlation between age and the cytokine levels in any of the groups (data not shown).
Discussion
Among other factors, TGFβ2 and SFRP1 have been implicated to be involved in glaucoma pathogenesis. In this study, we detected the presence of both TGFβ2 and SFRP1 in human AH samples. In cataract patients, the AH level of bioactive TGFβ2 was similar to many previously reported values [7] [8] [9] [10] [11] 14] . We also observed a significant elevation of active TGFβ2 in POAG patients, which is consistent with prior studies, although the magnitudes of changes were variable among the different studies [7] [8] [9] [10] [11] [12] 14] . Previous studies reported no correlation between AH level of active TGFβ2 and IOP in POAG patients [8, 9] , so did our findings.
In addition to POAG, our study evaluated TGFβ2 levels in PACG patients, divided into three groups: CACG, PACS and AACG. We found that the AH concentrations of active TGFβ2 in these groups were not significantly different from the cataract control group. However, when we assessed the correlation between IOP and TGFβ2 contents, we discovered a significant, positive correlation between these two parameters in the AACG group. This correlation was substantiated when the samples in the AACG group were sub-divided into patients whose IOP was controlled at ≤21 mmHg and those with high IOP. The TGFβ2 level in the high IOP sub-group was statistically significantly higher than that of the normal IOP sub-group. At this time, the biological and clinical significance of this finding is unclear. Nevertheless, we speculate that in the AACG patients with high IOP, there may have been inflammatory responses in the anterior segment of the eye, which may lead to an elevated level of TGFβ2 in the AH. Experiments are currently underway to test this hypothesis. Alternatively, a feed-forward relationship between ocular hypertension and TGFβ2 production may exist, as indicated by positive, though not significant, correlations in the POAG and CACG groups, such that a high IOP could augment AH level of TGFβ2. Since perfusion of ex vivo organ culture of human anterior segment with activated TGFβ2 increases IOP [17] , and intraocular injection of adenoviral encoding the bioactive TGFβ2 causes ocular hypertension in both the rat and mouse [23] , the increased TGFβ2 in AACG patients with high IOP may further exacerbate the glaucomatous conditions in the eye. Regardless, the contribution of TGFβ2 in ACG and clarification of these potential mechanisms deserve further careful evaluations.
We also measured the AH levels of SFRP1 in the same patients and found that they were not significantly different from that of the cataract control group. Wang and colleagues demonstrated that SFRP1 was overexpressed in TM tissues of POAG patients and in cultured TM cells derived from POAG donors [29] . They did not report the corresponding level in the AH. It is possible that because of the directional flow of AH, SFRP1 released in the TM quickly leaves the eye without adequate time for diffusion or equilibrium in the AH. Therefore, AH levels of SFRP1 do not reflect changes in the TM, and SFRP1 in AH likely comes from ocular tissues other than the TM. Similar to TGFβ2, we found that SFRP1 concentration was elevated in AH samples in the AACG with high IOP sub-group. Since this cytokine is shown to be involved in inflammatory response, this further indicates that inflammation may play a role in AACG with high IOP. Wang and coworkers also showed that perfusion with recombinant SFRP1 decreases aqueous outflow in perfusion organ culture of human anterior segment [29] . And intravitreal injection of adenoviral vector encoding SFRP1 raises IOP in the mouse [29] . The source and contribution of elevated levels of SFRP1 in AACG with high IOP are currently unknown, the significance of these findings requires additional research.
Moreover, unexpectedly, the SFRP1 level in POAG with high IOP was lower than the normal IOP subgroups. This regulation of SFRP1 expression is extremely intriguing. For the time being, the cause and the relationship to glaucoma pathogenesis of this finding are not apparent. It is possible that a feedback system exists, such that SFRP1 induces ocular hypertension, but high IOP reduces SFRP1 expression. This hypothesis will await future studies for clarification. We did not observe a difference between the high and normal IOP subgroups in CACG patients.
In the AACG group, we did not observe significant differences in AH levels of TGFβ2 and SFRP1 between patients treated with anti-glaucoma medications and those who were not treated. This finding suggests that drug treatment did not affect the concentrations of the two cell factors in AH.
In addition, this study showed that there was no correlation between age and the two cytokines, suggesting that age is not a determining factor of expressions of these two factors. Furthermore, there was no correlation between TGFβ2 and SFRP1 in the same samples. It reveals that levels of the two cytokines in the different glaucoma groups are not synchronous, and each has its own expression profile. Clearly, they each is associated with their respective signaling pathway and exerts their specific effects on the regulation of IOP. It will be highly interesting to find out if their effects are additional, synergistic, or antagonistic.
There are several limitations in this study. Even though we detected statistical significance in certain comparisons, we feel that the sample sizes in these study groups were still relatively small. We did not further sub-divide the patient groups according to the glaucoma medications they received. In addition, because of limitation of AH sample amount, we were not able to evaluate other cytokines which may play a role in glaucoma.
Conclusion
We detected TGFβ2 and SFRP1 in AH samples of the control and different glaucoma patients. We found that (1) POAG patients had a higher concentration of TGFβ2 in their AH, (2) AACG patients with high IOP had elevated levels of both cytokines compared to those with normal IOP, and (3) there was a difference in SFRP1 between normal and high IOP sub-groups in POAG patients. These results suggest that the relationships between glaucoma, IOP, and cytokine expression are very complicated. TGFβ2 and SFRP1 may play different roles in the pathogenesis and pathophysiology of different types of glaucoma. Glaucoma pathogenesis could be the result of many factors working together.
Additional files
Additional file 1: Figure S1 . Figure S2 . In the AACG groups, 8 AH samples were collected from patients who did not received glaucoma medications ("no drug" group), while 37 AH samples were from patients who were treated with beta-blockers, carbonic anhydrase inhibitors, and alpha-agonists (labeled as "drugs"). No statistically significant difference (p > 0.05) was observed on levels of TGFβ2 and SFRP1 between these two groups. 
